hotspot -WSS

hotspot

author：hotspot 2025-10-01 15:31:49 - browse：581

Cambridge: Biogen — Ruby Wallau for STAT

Biogen, the iconic but embattled biotech firm, is shuttering Biogen Digital Health, its roughly 150-person group focused on using new types of data like those from mobile phones and smart watches, and ending a clinical trial being conducted with Apple early, STAT has learned.

Biogen confirmed the organizational change, but said it might lean even more on digital tech startups in the future.

“It’s certainly not an abandonment of digital, it’s more of a realignment of resources and priorities,” said Adam Keeney, Biogen’s executive vice president and head of corporate development. However, he later acknowledged, Biogen Digital Health, a separate entity, “would no longer continue in its current form.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： H5N1 bird flu virus started spreading in cows in Texas in December

WSS

Key Senate committee drafts bipartisan bill to stem drug shortages

Bird flu outbreak in cows is latest avian flu curveball

Medicare bonuses could stop drug shortages under Senate plan

Cardiologists urge adding sexual orientation, gender identity to health records

Future doctors need a strong humanities education

Pumping milk in bathrooms at health conferences is common

entertainment

hotspot

hotspot

Supreme Court strikes down use of affirmative action

Diversity in clinical trials starts with building trust, experts say

Peter Hotez and the public health issue of online harassment

Key Senate committee drafts bipartisan bill to stem drug shortages

Alkermes shareholders re

Diversity in clinical trials starts with building trust, experts say

Heart attack and stroke risk calculators need revising

After traumatic brain injury, life support decisions can use more time

Anesthesiologist group: stop taking Ozempic before surgery

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

focus

High breast density mammograms need follow

There's an unseen cost to disruptive road

Prior authorization reform is both possible and imperative

Diversity in clinical trials starts with building trust, experts say

Dogs on Prozac: What pet anti

Inaction leaves children at risk from dangerous chemotherapy drug

knowledge

knowledge

focus

hotspot